GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
41.20
+0.05 (0.12%)
At close: Jun 6, 2025, 4:00 PM
41.20
0.00 (0.00%)
After-hours: Jun 6, 2025, 7:00 PM EDT
GSK Revenue
GSK had revenue of 7.52B GBP in the quarter ending March 31, 2025, with 2.08% growth. This brings the company's revenue in the last twelve months to 31.53B, up 2.57% year-over-year. In the year 2024, GSK had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.53B GBP
Revenue Growth
+2.57%
P/S Ratio
2.04
Revenue / Employee
459,412 GBP
Employees
68,629
Market Cap
82.94B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GSK News
- 4 days ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire
- 9 days ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 9 days ago - GSK, Spero to stop urinary tract infection drug trial due to early success - Reuters
- 9 days ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire
- 15 days ago - Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) - Business Wire
- 15 days ago - GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung' - Reuters
- 18 days ago - GSK's Blood-Cancer Treatment Combinations Approved in Japan - WSJ
- 23 days ago - GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - WSJ